Research
Alnylam says its Huntington’s RNA drug showed promise in an early study, but it is not yet clear whether it can slow disease progression.
The original reports on this story are listed below.
Drugs and FDA
In a phase 3 trial, intismeran plus Keytruda reduced melanoma recurrence or death risk by 42% versus Keytruda alone.
Insurance
KFF found the average family premium reached $28,303 in 2026, while workers paid an average $7,471 toward it, up 9%.
Infectious disease
The patient was severely immunocompromised and died in early October. Investigations into the infection and its possible role in the death are ongoing.
This Week in Medicine
The most important medical news of the week, summarized for you and easy to read. Every Sunday, free.
Free. No spam. Unsubscribe anytime.